Belantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. [1][6][7][2]

Jul 25, 2025 · Blenrep is used to treat relapsed or refractory (r/r) multiple myeloma (MM) in adults who have received at least 4 prior medicines, including an anti-CD38 monoclonal antibody, a …

3 days ago · GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the …

Jul 21, 2025 · BLENREP is administered in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone. The Product Monographs of the medications, used in …

Jul 23, 2025 · GSK is hoping to give Blenrep a second chance at the U.S. market after the FDA previously endorsed the drug in 2020 as a monotherapy in the fifth-line treatment of multiple …

Jul 25, 2025 · Blenrep specifically targets BCMA, a protein found on myeloma cells, and delivers chemotherapy directly to the cells. One of the most promising aspects of Blenrep is its …

May 23, 2025 · Blenrep is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) or has not responded to …

Watch this short video to explore BLENREP ︎ (belantamab mafodotin) mechanism of action BLENREP offers two different treatment combinations to meet your patients' needs: BVd and …

Oct 15, 2024 · Blenrep® (belantamab mafodotin) is a monoclonal antibody that targets B-cell maturation antigen (BCMA), a protein expressed on the surface of plasma cells, and releases …

Jul 17, 2025 · The FDA panel’s rejection highlights significant concerns about Blenrep’s safety and efficacy for treating multiple myeloma. A 5-3 vote against its overall benefit-risk …

Jan 10, 2023 · Blenrep (belantamab mafodotin-blmf) is a prescription injection used to treat multiple myeloma. Learn about cost, side effects, how it works, and more.

Aug 5, 2020 · BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory …

Jun 22, 2023 · BLENREP (belantamab mafodotin-blmf) for injection is a sterile, preservative-free, white to yellow, lyophilized powder in a single-dose vial for reconstitution and further dilution …

Aug 20, 2023 · Learn about Blenrep (belantamab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.

3 days ago · Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), …

Blenrep® (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) …

Jul 18, 2025 · GSK's multiple myeloma drug, Blenrep, faces uncertainty in the US market after an FDA advisory committee voted against its benefit/risk profile, despite strong clinical trial data …

BLENREP can cause changes to the surface of your eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and corneal ulcer. Tell your healthcare provider if you …

Jul 17, 2025 · The US FDA Oncologic Drugs Advisory Committee voted against the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.

Aug 6, 2020 · BLENREP is the first approved anti-BCMA therapy and has the potential to transform the treatment of patients with relapsed or refractory myeloma who have limited …

Sep 17, 2020 · On 23 February 2024, the European Commission issued a decision to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) in the European …

Aug 12, 2025 · Blenrep represents a major development in the treatment of multiple myeloma. Shutterstock Dubai: The Emirates Drug Establishment (EDE) has announced the registration …

Jul 21, 2025 · ODAC votes against belantamab mafodotin in combination with bortezomib and dexamethasone (3-5), and in combination with pomalidomide and dexamethasone (1-7); FDA …

BLENREP comes in the following dosage form: BLENREP is provided as a powder in a single-use vial that is reconstituted and diluted for intravenous Infusion. BLENREP is a white to yellow …

Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective and accessible options are needed1,2,3 Sixth regulatory approval for …